Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

CONCLUSIONS: In patients with recent acute coronary syndrome and elevated atherogenic lipoproteins, MACEs increased across baseline apoB strata. Alirocumab reduced MACEs across all strata of baseline apoB, with larger absolute reductions in patients with higher baseline levels. Lower achieved apoB was associated with lower risk of MACEs, even after accounting for achieved low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol, indicating that apoB provides incremental information. Achievement of an apoB level ≤35 mg/dL may reduce lipoprotein-attributable residual risk after acute coronary syndrome.REGISTRATION: URL: https://www.CLINICALTRIALS: gov. Unique identifier: NCT01663402.PMID:35770629 | DOI:10.1161/CIRCULATIONAHA.121.057807

Source: Circulation - June 30, 2022 Category: Cardiology Authors: Emil Hagstr öm P Gabriel Steg Michael Szarek Deepak L Bhatt Vera A Bittner Nicolas Danchin Rafael Diaz Shaun G Goodman Robert A Harrington J Wouter Jukema Evangelos Liberopoulos Nikolaus Marx Jennifer McGinniss Garen Manvelian Robert Pordy Michel Scemama Source Type: research